Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis

NCT00401271 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Tuberculosis

Interventions

DRUG: OPC-67683
DRUG: Rifafour e-275

Sponsor

Otsuka Frankfurt Research Institute GmbH